211 related articles for article (PubMed ID: 34697065)
1. Fusion of the Paired Box 3 (
Panagopoulos I; Gorunova L; Andersen K; Lund-Iversen M; Tafjord S; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(6):723-734. PubMed ID: 34697065
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum.
Le Loarer F; Laffont S; Lesluyes T; Tirode F; Antonescu C; Baglin AC; Delespaul L; Soubeyran I; Hostein I; Pérot G; Chibon F; Baud J; Le Guellec S; Karanian M; Costes-Martineau V; Castain C; Eimer S; Le Bail B; Wassef M; Coindre JM
Am J Surg Pathol; 2019 Jun; 43(6):747-754. PubMed ID: 30829729
[TBL] [Abstract][Full Text] [Related]
3. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
5. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
Schmitt-Ney M; Camussi G
PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
[TBL] [Abstract][Full Text] [Related]
6. Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation.
Huang SC; Ghossein RA; Bishop JA; Zhang L; Chen TC; Huang HY; Antonescu CR
Am J Surg Pathol; 2016 Jan; 40(1):51-9. PubMed ID: 26371783
[TBL] [Abstract][Full Text] [Related]
7. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.
Wachtel M; Dettling M; Koscielniak E; Stegmaier S; Treuner J; Simon-Klingenstein K; Bühlmann P; Niggli FK; Schäfer BW
Cancer Res; 2004 Aug; 64(16):5539-45. PubMed ID: 15313887
[TBL] [Abstract][Full Text] [Related]
8. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J
Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764
[TBL] [Abstract][Full Text] [Related]
10. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
[TBL] [Abstract][Full Text] [Related]
11. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract][Full Text] [Related]
12. Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon.
Meyer A; Klubíčková N; Mosaieby E; Grossmann P; Kalmykova A; Koshyk O; Michal M
Virchows Arch; 2023 Apr; 482(4):777-782. PubMed ID: 36719455
[TBL] [Abstract][Full Text] [Related]
13. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
[TBL] [Abstract][Full Text] [Related]
14. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
15. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
[TBL] [Abstract][Full Text] [Related]
16. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
[TBL] [Abstract][Full Text] [Related]
17. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
18. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
[TBL] [Abstract][Full Text] [Related]
20. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
